Interim report January – September 2023November 28, 2023

Extraordinary General Meeting 2023October 5, 2023

Annual Report 2022

Press releases

November 29, 2023Correction: NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROMORE PHARMA AB (PUBL)
November 29, 2023NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROMORE PHARMA AB (PUBL)
November 29, 2023Promore Pharma AB intends to carry out a reverse acquisition of PMD Device Solutions AB
November 28, 2023Interim report, January-September 2023
October 12, 2023Promore Pharma initiates voluntary liquidation

More Press Releases

Interim report January – September 2023

Promore Pharma AB (publ) published the interim report for January – September 2023 on November 28, 2023.

Report

Read the report

Calendar

December 29, 2023Extraordinary General Meeting December 2023

More Events

Promore Pharma in Media

Here we present media releases, interviews, images and videos.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate of approximately 6 percent and is expected to reach USD 12 billion in 2024.